Cargando…

PD-1 immune checkpoint blockade may be viable for the prevention and treatment of elderly patients with POCD [Letter]

Detalles Bibliográficos
Autores principales:	Wei, Penghui, Yang, Fan, Li, Jianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489592/ https://www.ncbi.nlm.nih.gov/pubmed/31114176 http://dx.doi.org/10.2147/CIA.S197925

Ejemplares similares

Difference in GFAP Levels in POCD and Non-POCD Patients After on Pump CABG
por: Nurcahyo, Widya Istanto, et al.
Publicado: (2022)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
por: Banck, Jan Christoph, et al.
Publicado: (2021)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Identification of individuals at risk for postoperative cognitive dysfunction (POCD)
por: Yang, Xiao, et al.
Publicado: (2022)

Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
por: Peng, Ling, et al.
Publicado: (2021)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Role of Dexmedetomidine in Early POCD in Patients Undergoing Thoracic Surgery
por: Ran, Jiao, et al.
Publicado: (2021)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
por: Perrotta, Fabio, et al.
Publicado: (2019)

Study on painless gastroscopy and POCD of smoking patients under general anesthesia
por: Yu, Wan‐Qiu, et al.
Publicado: (2022)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Response: Letter to FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in silico study
por: Asadi‐Pooya, Ali A.
Publicado: (2023)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
por: Kadam, Pournima, et al.
Publicado: (2020)

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

Cyclic adenosine monophosphate potentiates immune checkpoint blockade therapy in acute myeloid leukemia
por: Mao, Ping, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d3gvrsv8egfrs8ehe326u6o0nd